Tianxing Healthcare (01609) plans to repurchase no more than 2.9 million H shares

According to Zhitong Finance App, Tianxing Healthcare (01609) issued an announcement. At the company's 2025 annual shareholders' meeting held on June 26, 2026, shareholders reviewed and approved the “Proposal on Granting General Authorization to Repurchase H Shares”, granting the board of directors general authorization to repurchase the company's H shares. According to the repurchase authorization, the company was authorized to repurchase no more than 10% of the total number of H shares issued on the day the relevant resolution was passed (i.e. 5,483,134 H shares). The board of directors has decided to implement the H share repurchase plan in due course under the repurchase authorization. During the validity period of the repurchase authorization, the company's H shares will be repurchased on the open market from time to time on the premise of complying with the Hong Kong Stock Exchange Limited securities listing rules, articles of association and applicable laws and regulations. The cumulative maximum number of H shares repurchased shall not exceed 2.9 million H shares, which is equivalent to about 5.29% of the total number of H shares issued by the company on the date of this announcement. According to section 10.06 of the listing rules, the price paid by the company when repurchasing shares shall not be higher than 105% of the average closing price reported by the Stock Exchange on the five trading days immediately prior to the relevant repurchase transaction.